Pandemic News and Research

RSS

A pandemic is a global disease outbreak. During a pandemic, transmission can be anticipated in the workplace, not only from patient to workers in health care settings, but also among co-workers in general work settings. A pandemic would cause high levels of illness, death, social disruption, and economic loss. Everyday life would be disrupted because so many people in so many places become seriously ill at the same time. Impacts could range from school and business closings to the interruption of basic services such as public transportation and food delivery.

Non-invasive 'swine flu' breath test could help ease future vaccine shortages

A test, novel breath measuring the immune response to the H1N1 flu virus, could help to ease future vaccine shortages by identifying the people who have already been infected with the flu virus.

15 Jul 2011

Studies show AIDS drugs can prevent heterosexuals from acquiring HIV

Two new studies released early Wednesday show that AIDS drugs can prevent heterosexuals from acquiring HIV, adding to a growing number of new methods to slow the spread of the virus world-wide.

14 Jul 2011

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation.

14 Jul 2011

'Sex' between viruses can create new influenza pandemic

A new University of Maryland-led study finds that 'sex' between the virus responsible for the 2009 flu pandemic (H1N1) and a common type of avian flu virus (H9N2) can produce offspring -- new combined flu viruses -- with the potential for creating a new influenza pandemic.

14 Jul 2011

Swine flu vaccine and risk of Guillain-Barré Syndrome

In a large five nation study from Europe it was seen that the use of adjuvanted vaccines against the pandemic H1N1 influenza virus probably did not increase the risk of Guillain-Barré Syndrome (GBS), but the investigators could not firmly rule out a slightly greater chance of suffering the paralytic condition.

13 Jul 2011

First Edition: July 13, 2011

Today's headlines detail the next moves in the ongoing budget discussion, including a "last-choice option" proposed by Senate Minority Leader Mitch McConnell, R-Ky., and reports about how the health industry is lining up against possible cuts.

13 Jul 2011

iBio successfully produces human plasma proteins using proprietary technology

iBio, Inc. today announced successful production of human plasma proteins using its proprietary iBioLaunch technology. Human alpha 1-antitrypsin and human C1 esterase inhibitor were successfully produced at high yield in green plants via the Company's proprietary iBioLaunch technology. Both of these proteins are important therapeutic products, but until now they have been made from human blood.

11 Jul 2011

Insights into why doctors are reluctant to disclose patient information

Family doctors are reluctant to disclose identifiable patient information, even in the context of an influenza pandemic, mostly in an effort to protect patient privacy.

11 Jul 2011

Flu vaccine against all strains of virus coming soon

A universal flu vaccine, capable of working against all strains, would save lives and money by eliminating the need for the annual jab say experts. Researchers in California and the Netherlands believe they are now a “step closer” to meeting this objective.

10 Jul 2011

Collaborative research discovers broadly acting antibody against influenza viruses

Annually changing flu vaccines with their hit-and-miss effectiveness may soon give way to a single, near-universal flu vaccine, according to a new report from scientists at The Scripps Research Institute and the Dutch biopharmaceutical company Crucell. They describe an antibody that, in animal tests, can prevent or cure infections with a broad variety of influenza viruses, including seasonal and potentially pandemic strains.

8 Jul 2011

Science should inform global AIDS policy

Thirty years have passed since the first reported case of AIDS, and "we now have an unprecedented opportunity, based on solid scientific data, to control and ultimately end the AIDS pandemic," after decades of the idea being "a distant aspiration because we lacked sufficient evidence-based tools to convert the hope to reality," Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, writes in a Science editorial.

2 Jul 2011

Positive final results from Medicago's H5N1 Avian Influenza VLP vaccine Phase II trial

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive final results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.

30 Jun 2011

GAO reports on government response to H1N1 pandemic

GAO on Monday published two reports on the government's response to the 2009 H1N1 influenza pandemic.

29 Jun 2011

Australian Nobel Prize winner closer to delivering vaccines in food after positive first study in humans

The Australian scientist who won a Nobel Prize for identifying a cancer-causing stomach bacterium, today said a clinical trial had shown that some strains of the bacteria (Helicobacter pylori or H. pylori) were safe and well tolerated in humans.

27 Jun 2011

Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

CEL-SCI Corporation announced today that its partner Teva Pharmaceuticals, a leading global pharmaceutical company, has concluded the Site Initiation Visit for the first Israeli clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy.

27 Jun 2011

Biota reports preliminary data from CS-8958 Phase III trial against influenza

Dr Seizaburo Kashiwagi presented the preliminary data from an influenza Phase III prophylaxis study conducted during the 2009/2010 pandemic flu season in Japan.

27 Jun 2011

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that its Taiwanese partner, Orient Europharma, has concluded the Site Initiation Visit for the first Taiwanese clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy. The first center is called Shin Kong Wu Ho-Su Memorial Hospital and is located in Taipei, Taiwan.

24 Jun 2011

Mothers receiving influenza vaccination during pregnancy also protect infants

Infants born to mothers who received the influenza (flu) vaccine while pregnant are nearly 50 percent less likely to be hospitalized for the flu than infants born to mothers who did not receive the vaccine while pregnant, according to a new collaborative study by researchers at Wake Forest Baptist Medical Center and colleagues.

23 Jun 2011

CEL-SCI announces results from Multikine Phase II trial on head and neck cancer

CEL-SCI Corporation announced today data from its Phase II clinical studies which showed that its lead drug Multikine was able to lower cholesterol in studies involving 120 head and neck cancer patients.

22 Jun 2011

Public Health Grid technology could address specific surveillance needs for pandemic disease control

An evaluation of the Public Health Grid (PHGrid) technology during the 2009 H1N1 influenza pandemic could enhance the capabilities of epidemiologists and disease-control agencies when the next emergent disease appears, according to a study published in the International Journal of Grid and Utility Computing.

17 Jun 2011

Pandemic News and Research

Further Reading

Non-invasive 'swine flu' breath test could help ease future vaccine shortages

Studies show AIDS drugs can prevent heterosexuals from acquiring HIV

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

'Sex' between viruses can create new influenza pandemic

Swine flu vaccine and risk of Guillain-Barré Syndrome

First Edition: July 13, 2011

iBio successfully produces human plasma proteins using proprietary technology

Insights into why doctors are reluctant to disclose patient information

Flu vaccine against all strains of virus coming soon

Collaborative research discovers broadly acting antibody against influenza viruses

Science should inform global AIDS policy

Positive final results from Medicago's H5N1 Avian Influenza VLP vaccine Phase II trial

GAO reports on government response to H1N1 pandemic

Australian Nobel Prize winner closer to delivering vaccines in food after positive first study in humans

Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

Biota reports preliminary data from CS-8958 Phase III trial against influenza

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

Mothers receiving influenza vaccination during pregnancy also protect infants

CEL-SCI announces results from Multikine Phase II trial on head and neck cancer

Public Health Grid technology could address specific surveillance needs for pandemic disease control

Best practices - optimize qPCR processes for pathogen detection eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News